Pfizer's Arthritis Drug Xeljanz (tofacitinib citrate) should not be approved for the treatment of rheumatoid arthritis, CHMP (Committee for Medicinal Products for Human Use) advised the European Medicines Agency on April 25th, 2013. Pfizer can request a re-examination of the opinion with the next 15 days, EMA (European Medicines Agency) informed...

Read more...